Cargando…
Cabergoline Withdrawal Before and After Menopause: Outcomes in Microprolactinomas
Natural course of prolactinomas after menopause is not fully elucidated. The aim of this study was to compare recurrence rate after cabergoline withdrawal in premenopausal vs. postmenopausal women with microprolactinoma. Sixty-two women with microprolactinoma treated with cabergoline for at least 1 ...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10355708/ https://www.ncbi.nlm.nih.gov/pubmed/31001736 http://dx.doi.org/10.1007/s12672-019-00363-4 |
_version_ | 1785075155707363328 |
---|---|
author | Indirli, Rita Ferrante, Emanuele Sala, Elisa Giavoli, Claudia Mantovani, Giovanna Arosio, Maura |
author_facet | Indirli, Rita Ferrante, Emanuele Sala, Elisa Giavoli, Claudia Mantovani, Giovanna Arosio, Maura |
author_sort | Indirli, Rita |
collection | PubMed |
description | Natural course of prolactinomas after menopause is not fully elucidated. The aim of this study was to compare recurrence rate after cabergoline withdrawal in premenopausal vs. postmenopausal women with microprolactinoma. Sixty-two women with microprolactinoma treated with cabergoline for at least 1 year and followed for 2 years after drug withdrawal were retrospectively selected. Patients were divided into two groups: 48 patients stopped cabergoline before menopause (“PRE” group), while 14 after menopause (“POST” group). Recurrence was defined by prolactin levels above normal, confirmed on two occasions. Overall, 39/62 women relapsed. Patients who relapsed apparently had higher prolactin before withdrawal (median 216.2, range 21.2–464.3 mIU/L) compared with those in long-term remission (94.3, 29.7–402.8 mIU/L; p < 0.05), and the risk of recurrence seemed lower in POST women (4/14, 29%) than in PRE ones (35/48, 73%, p < 0.005, OR 0.149, 95% CI 0.040–0.558). However, none of the factors (prolactin before withdrawal, menopausal status, treatment duration, complete adenoma regression) showed a correlation with recurrence risk in multivariate analysis. The best strategy able to optimize CBG treatment and withdrawal’s outcomes is still to be defined in microprolactinomas. Postmenopausal status cannot reliably predict long-term remission, and follow-up is needed also in women of this age. |
format | Online Article Text |
id | pubmed-10355708 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-103557082023-07-21 Cabergoline Withdrawal Before and After Menopause: Outcomes in Microprolactinomas Indirli, Rita Ferrante, Emanuele Sala, Elisa Giavoli, Claudia Mantovani, Giovanna Arosio, Maura Horm Cancer Original Paper Natural course of prolactinomas after menopause is not fully elucidated. The aim of this study was to compare recurrence rate after cabergoline withdrawal in premenopausal vs. postmenopausal women with microprolactinoma. Sixty-two women with microprolactinoma treated with cabergoline for at least 1 year and followed for 2 years after drug withdrawal were retrospectively selected. Patients were divided into two groups: 48 patients stopped cabergoline before menopause (“PRE” group), while 14 after menopause (“POST” group). Recurrence was defined by prolactin levels above normal, confirmed on two occasions. Overall, 39/62 women relapsed. Patients who relapsed apparently had higher prolactin before withdrawal (median 216.2, range 21.2–464.3 mIU/L) compared with those in long-term remission (94.3, 29.7–402.8 mIU/L; p < 0.05), and the risk of recurrence seemed lower in POST women (4/14, 29%) than in PRE ones (35/48, 73%, p < 0.005, OR 0.149, 95% CI 0.040–0.558). However, none of the factors (prolactin before withdrawal, menopausal status, treatment duration, complete adenoma regression) showed a correlation with recurrence risk in multivariate analysis. The best strategy able to optimize CBG treatment and withdrawal’s outcomes is still to be defined in microprolactinomas. Postmenopausal status cannot reliably predict long-term remission, and follow-up is needed also in women of this age. Springer US 2019-04-18 /pmc/articles/PMC10355708/ /pubmed/31001736 http://dx.doi.org/10.1007/s12672-019-00363-4 Text en © The Author(s) 2019 https://creativecommons.org/licenses/by/4.0/Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Original Paper Indirli, Rita Ferrante, Emanuele Sala, Elisa Giavoli, Claudia Mantovani, Giovanna Arosio, Maura Cabergoline Withdrawal Before and After Menopause: Outcomes in Microprolactinomas |
title | Cabergoline Withdrawal Before and After Menopause: Outcomes in Microprolactinomas |
title_full | Cabergoline Withdrawal Before and After Menopause: Outcomes in Microprolactinomas |
title_fullStr | Cabergoline Withdrawal Before and After Menopause: Outcomes in Microprolactinomas |
title_full_unstemmed | Cabergoline Withdrawal Before and After Menopause: Outcomes in Microprolactinomas |
title_short | Cabergoline Withdrawal Before and After Menopause: Outcomes in Microprolactinomas |
title_sort | cabergoline withdrawal before and after menopause: outcomes in microprolactinomas |
topic | Original Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10355708/ https://www.ncbi.nlm.nih.gov/pubmed/31001736 http://dx.doi.org/10.1007/s12672-019-00363-4 |
work_keys_str_mv | AT indirlirita cabergolinewithdrawalbeforeandaftermenopauseoutcomesinmicroprolactinomas AT ferranteemanuele cabergolinewithdrawalbeforeandaftermenopauseoutcomesinmicroprolactinomas AT salaelisa cabergolinewithdrawalbeforeandaftermenopauseoutcomesinmicroprolactinomas AT giavoliclaudia cabergolinewithdrawalbeforeandaftermenopauseoutcomesinmicroprolactinomas AT mantovanigiovanna cabergolinewithdrawalbeforeandaftermenopauseoutcomesinmicroprolactinomas AT arosiomaura cabergolinewithdrawalbeforeandaftermenopauseoutcomesinmicroprolactinomas |